Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Machaon who wrote (18722)	4/6/1998 9:39:00 PM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

Bob, Thanks for the update. I have been running around with soccer and baseball and haven't had a chance to hear any updates (other than a CNBC interview with someone from ZEN). The story is quite straight forward. The trial was stopped because the data was consistent with early data. Tamoxifen "works" for prevention in an "at risk" population, but it's risks are fairly well known. LGND is in excellent shape for future applications. They are well positioned in second generation SERMs (see home.att.net ) and have a commanding lead in Rexinoids. The street will figure this out sooner or later.

To: Machaon who wrote (18722)	4/6/1998 10:00:00 PM
From: dwight martin	Read Replies (2) \| Respond to of 32384

On CBS they also talked about the newer SERMs. Rather mentioned what I thought was Raloxifene (if that makes sense), not Droloxifene, showing a 67% preventative effect compared to the 45% with Tamoxifen and with fewer side effects. Made it sound like something was going to happen with pretty quickly with the newer SERMs.